If you have had RF microneedling, HIFU skin tightening, or a picosecond laser treatment in the last five years, there is a reasonable chance the device was designed, engineered, and manufactured in South Korea. Sylfirm X, Vivace, Lutronic lasers, Oligio HIFU — these are Korean-developed platforms now used in thousands of US clinics.
South Korea's aesthetic device market was valued at approximately $332 million in 2025 and is projected to reach $476 million by 2031, growing at 6.4% CAGR (Mordor Intelligence, 2026). The country is both a major consumer and a major exporter of aesthetic technology, and its manufacturers have moved from copying Western devices to leading innovation in RF microneedling, high-intensity focused ultrasound (HIFU), and picosecond lasers.
Understanding where a device comes from, who approved it, and how it reached the US market matters for patients choosing treatments and for providers evaluating capital equipment purchases.
The Major Korean Aesthetic Device Manufacturers
Several South Korean companies now play significant roles in the global aesthetic device market:
Viol Co., Ltd. (Sylfirm X, Scarlet S)
Viol, based in Gyeonggi-do, South Korea, manufactures Sylfirm X — one of the most widely adopted RF microneedling devices in the US market. Sylfirm X received FDA 510(k) clearance (K213612) and is distributed in the US by BENEV Company. The device features eight dual-wave RF delivery modes — four continuous wave (CW) and four pulsed wave (PW) — allowing practitioners to address both skin laxity and vascular/pigment concerns with the same platform. Viol has been aggressive about patent enforcement: in 2024, the US International Trade Commission (USITC) probe led to settlements with multiple companies accused of infringing Viol's microneedle RF patents.
SHEnB Co., Ltd. (Vivace)
Seoul-based SHEnB manufactures the Vivace RF microneedling device, which received FDA 510(k) clearance (K193070) in 2021. Distributed in the US by Aesthetics Biomedical, Vivace uses a 36-needle electrode array with bipolar RF energy. The 510(k) submission lists SHEnB's Seoul facility as the manufacturer, with Aesthetics Biomedical in Phoenix, Arizona as the US correspondent.
Lutronic Corporation
Lutronic, headquartered in Seoul, is one of Korea's oldest aesthetic laser companies. The company produces picosecond, Q-switched Nd:YAG, fractional CO₂, and RF microneedling devices. Lutronic has its own US subsidiary and a portfolio of FDA 510(k) clearances spanning laser and RF platforms. The company was among the first Korean aesthetic device makers to establish direct US distribution.
Jeisys Medical Inc.
Jeisys, based in Seoul, manufactures the Genius RF microneedling device (formerly Infini) and the CO₂RE fractional laser platform. The company was named in the USITC investigation into Viol's patent claims, and its devices compete directly in the US RF microneedling market.
Classys Inc. (Oligio, Shurink)
Classys, based in Seoul, manufactures Oligio (a monopolar RF skin-tightening platform) and the Shurink series of HIFU devices. The Shurink line is one of the most popular HIFU platforms in East Asian clinics and has been expanding into Western markets through distributor networks.
How Korea's MFDS Regulates Aesthetic Devices
South Korea's Ministry of Food and Drug Safety (MFDS) — formerly the Korea Food and Drug Administration (KFDA) — has regulated medical devices since 2017, when oversight was consolidated under the Medical Device Act.
Device classification
The MFDS classifies medical devices into four classes:
| Class | Risk Level | Typical Examples | Approval Pathway |
|---|---|---|---|
| Class I | Low | Manual microneedling rollers, some topical applicators | Notification (self-certification) |
| Class II | Low-Moderate | Some lasers, basic RF devices | Notification or MFDS review |
| Class III | Moderate-High | Advanced RF platforms, HIFU, most aesthetic energy devices | MFDS approval required |
| Class IV | High | Implantable devices, novel combination products | MFDS approval with clinical data |
Most aesthetic energy-based devices fall into Class III or IV, requiring formal MFDS review. For Class II devices in category 4 ("New Devices") and Class III/IV devices, manufacturers must submit a full application to MFDS with technical documentation. Review takes approximately 60 to 80 days, with fees ranging from approximately $600 to $1,200 depending on device class.
2025–2026 regulatory changes
The MFDS has been updating its regulatory framework:
- Amendments to Enforcement Rules (effective July 2025): Strengthened administrative sanctions for manufacturers and importers who obtain permits through false or fraudulent means. The MFDS may now cancel approvals or order facility closures.
- Real-World Evidence (RWE) submissions: MFDS now accepts real-world evidence in support of device approval, expanding the evidence base beyond traditional clinical trials.
- Long-term follow-up designations: MFDS may designate certain devices for long-term follow-up when adverse events occur annually or when serious risks (death, irreversible harm) are possible after implantation.
- Revised Medical Device Standards (effective July 2026): Updated technical standards reflecting strengthened safety oversight and harmonization with international standards.
For Class IV devices, manufacturers must submit technical documentation in STED (Summary Technical Document) format. For Classes II and III, STED submission is voluntary.
MFDS fast-track review
MFDS offers a fast-track review pathway for innovative medical devices, shortening the approval timeline to approximately 12 months for hybrid devices. However, Class III lasers still face costly clinical trial requirements and strict post-market surveillance obligations.
From MFDS to FDA: How Korean Devices Enter the US Market
A Korean aesthetic device that is MFDS-approved in South Korea cannot simply be sold in the US. It must go through the FDA's regulatory process — almost always the 510(k) pathway for Class II devices.
The typical pathway
MFDS approval in Korea. The manufacturer develops the device and obtains MFDS clearance to sell in South Korea. This establishes the device's baseline safety and performance data.
Identify an FDA predicate. The manufacturer (or their US distributor) identifies a legally marketed US device with a similar intended use and technological profile to serve as the 510(k) predicate.
Establish US presence. Korean manufacturers typically work through US-based distributors or establish their own US subsidiaries. The US correspondent handles FDA communications, registration, and distribution logistics. For example, Viol works through BENEV Company, and SHEnB works through Aesthetics Biomedical.
510(k) submission. The submission package includes device description, comparison to the predicate, performance testing (bench and sometimes clinical), and labeling. The standard user fee is $24,335 (FY 2025), or $6,084 for small businesses.
FDA clearance. If the FDA agrees the device is substantially equivalent to the predicate, the manufacturer receives clearance and may begin marketing in the US.
Post-market compliance. Ongoing obligations include establishment registration, device listing, adverse event reporting, and compliance with the new Quality Management System Regulation (QMSR), which aligned with ISO 13485:2016 in February 2026.
What MFDS approval does and does not mean for US patients
MFDS approval indicates that a Korean regulatory body has reviewed the device's safety and performance data for the Korean market. It does not substitute for FDA clearance. A device can be MFDS-approved but not FDA-cleared, meaning it is legally sold in Korea but not in the United States.
The FDA's 510(k) process evaluates substantial equivalence to a US predicate device — it does not simply accept MFDS approval as sufficient evidence. However, MFDS approval data (including clinical study results) can support the 510(k) submission package.
Why Korean Device Provenance Matters for Patients
When a clinic tells you they are using a Korean-made device, that information alone does not tell you whether it is safe, effective, or legally marketed in the US. Here is what to ask:
- Is the device FDA-cleared for the specific use being proposed? MFDS approval is separate from FDA clearance. Search the FDA 510(k) database by device name or manufacturer.
- Who is the US distributor? Korean manufacturers work through authorized US distributors. Devices imported through unauthorized channels may be grey-market products without FDA clearance or manufacturer warranty support.
- Has the provider been trained on this specific device? Manufacturer training programs vary. Devices with complex RF delivery modes (like Sylfirm X's eight CW/PW modes) require specific training to use safely and effectively.
- Is the device being used within its FDA-cleared indication? Off-label use is common in aesthetic medicine but carries different risk profiles than on-label use.
Why This Matters for Providers and Practice Owners
Korean devices often offer competitive pricing compared to Western manufacturers — sometimes 30–50% less for comparable platforms. But the purchase decision involves more than acquisition cost:
- Regulatory due diligence. Verify that the specific model and configuration you are purchasing has an active FDA 510(k) clearance. Some Korean manufacturers sell multiple models in Korea, only some of which have US clearance.
- Service and support infrastructure. Devices sold through authorized US distributors typically come with service contracts, technical support, and replacement parts. Grey-market imports may not.
- Intellectual property risk. The USITC investigation into Viol's patent portfolio led to settlements with several manufacturers. Providers should understand whether a device they are evaluating has any outstanding IP disputes.
- Predicate chain evaluation. The 510(k) system means every device traces back to a predicate. Understanding the predicate chain helps evaluate whether a device's safety profile is built on solid evidence.
- Reimbursement and insurance. Malpractice carriers increasingly ask whether devices used in a practice are FDA-cleared for the specific procedures performed. Using uncleared devices may affect coverage.
The Bigger Picture: Korea's Role in Aesthetic Innovation
Korean aesthetic device manufacturers have moved beyond imitation into genuine innovation. The dual-wave RF technology in Sylfirm X, the multi-electrode arrays in Vivace, and the HIFU advances in Shurink represent engineering contributions that are now being adopted globally. Korea's domestic aesthetic market — projected to reach approximately $1.36 billion by 2035 (Market Research Future, 2026) — provides manufacturers with a sophisticated home market that drives rapid iteration.
For manufacturers and regulatory teams navigating the Korean side of this equation — whether registering a device with the MFDS, understanding Korea-specific classification requirements, or developing a market-entry strategy for South Korea — KoreaMedGlobal covers South Korea medical device and healthcare market access, including MFDS registration requirements, regulatory timelines, and Korea market-entry strategy.
The Bottom Line
South Korea is a major force in aesthetic device manufacturing, and Korean-made devices are increasingly common in US clinics. But "Korean-made" does not automatically mean "FDA-cleared," and MFDS approval does not substitute for FDA review. Patients should verify that any device used on them has active FDA clearance for the specific treatment being performed. Providers should conduct the same regulatory due diligence they would apply to any capital equipment purchase — checking clearance status, authorized distribution channels, service infrastructure, and IP status before committing.
Sources
- Mordor Intelligence, "South Korea Aesthetic Devices Market Size & Share Analysis — Growth Trends & Forecasts (2026–2031)." https://www.mordorintelligence.com/industry-reports/south-korea-aesthetic-devices-market
- Market Research Future, "South Korea Medical Aesthetics Market Size & Trends 2035." https://www.marketresearchfuture.com/reports/south-korea-medical-aesthetics-market-44966
- U.S. FDA, 510(k) Summary K213612, SYLFIRM X™, VIOL Co., Ltd. https://www.accessdata.fda.gov/cdrh_docs/pdf21/K213612.pdf
- U.S. FDA, 510(k) Summary K193070, VIVACE Electrosurgical Device, SHEnB Co., Ltd. https://www.accessdata.fda.gov/cdrh_docs/pdf19/K193070.pdf
- BusinessWire, "Scarlet and Sylfirm X Gain Momentum as Serendia Reaches Settlements in ITC Patent Infringement Case," June 18, 2024. https://www.businesswire.com/news/home/20240618176340/en
- BioSpace, "BENEV Launches Sylfirm X Ultimate Edition in the U.S.," April 26, 2021. https://www.biospace.com/benev-launches-sylfirm-x-ultimate-edition-a-novel-radiofrequency-micro-needling-device-in-the-u-s-as-the-exclusive-distributor
- QualTechs, "Korea MFDS Amendments to Medical Device Enforcement Rules & Standards 2025–2026." https://www.qualtechs.com/en-gb/article/korea-mfds-medical-device-rules-standards-2025
- Johner Institute, "South Korea: An Interesting Market for Medical Device Manufacturers." https://blog.johner-institute.com/regulatory-affairs/south-korea
- Coherent Market Insights, "Medical Aesthetic Devices Market Share & Forecast, 2026–2033." https://www.coherentmarketinsights.com/market-insight/medical-aesthetic-devices-market-5336
